| Literature DB >> 27268298 |
Yusuke Higuchi1, Kenji Tokunaga1, Yuko Watanabe1, Toshiro Kawakita2, Naoko Harada2, Shunichiro Yamaguchi1, Kisato Nosaka3, Hiroaki Mitsuya1, Norio Asou4.
Abstract
We present a patient with T-cell lymphoblastic lymphoma (T-LBL) harboring t(6;11)(q27;q23) that converted to acute monoblastic leukemia at relapse. A 27-year-old man developed T-LBL with a mediastinal mass. He exhibited several recurrences in the central nervous system and marrow. A fifth relapse occurred in the marrow, with 42.8% blasts with CD4, CD5, CD7, CD10, CD33, CD34, HLA-DR and cytoplasmic (cy) CD3. While achieving complete remission with nelarabine, sixth relapse occurred in the marrow with 6.8% blasts, which had characteristics of monoblastic features, 2 months later. Marrow blasts were positive for myeloperoxidase, CD4, CD33, CD56, CD64, and HLA-DR, but were negative for cyCD3, CD5, CD7, CD10, and CD34. Marrow cells at both the 5th lymphoid and 6th myeloid relapses had t(6;11)(q27;q23) and the same MLL-MLLT4 fusion transcript. In addition, the MLL-MLLT4 fusion sequences documented in the initial mediastinal cells were the same as seen in peripheral blood cells at the 6th relapse. The patient continues 7th remission after one course of gemtuzumab ozogamicin therapy followed by cord blood transplantation for more than 3 years. Sequential phenotypic and cytogenetic studies may yield valuable insights into the mechanism of leukemic recurrence and possible implications for treatment selection.Entities:
Keywords: Lineage switch; MLL-MLLT4 (AF6); T-cell lymphoblastic lymphoma; acute monoblastic leukemia; t(6;11)(q27;q23)
Mesh:
Year: 2016 PMID: 27268298 DOI: 10.1016/j.cancergen.2016.05.070
Source DB: PubMed Journal: Cancer Genet